APO Research
Talk to an analyst

APO RESEARCH · REPORT

Insulin Glargine Injection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Insulin Glargine Injection Market Outlook and Growth Opportunities 2026

22 December 2025197 pages

Choose your research edition.

Industry ResearchInsulin Glargine Injection Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Insulin Glargine Injection Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Insulin Glargine Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Insulin Glargine Injection Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Insulin Glargine Injection Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Insulin Glargine Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Insulin Glargine Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Insulin Glargine Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Insulin Glargine Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Insulin Glargine Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Insulin Glargine Injection market include Tonghua Dongbao Pharmaceutical, Sanofi, Boao Bio Harmaceutical, Lilly, Gan & Lee and HEC Pharm, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Insulin Glargine Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Insulin Glargine Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Insulin Glargine Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Insulin Glargine Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Insulin Glargine Injection Segment by Company

Tonghua Dongbao Pharmaceutical

Sanofi

Boao Bio Harmaceutical

Lilly

Gan & Lee

HEC Pharm

Insulin Glargine Injection Segment by Type

Pre-filled

Ordinary

Insulin Glargine Injection Segment by Application

Hospital

Clinic

Insulin Glargine Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Insulin Glargine Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Insulin Glargine Injection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Insulin Glargine Injection significant trends, drivers, influence factors in global and regions.

6. To analyze Insulin Glargine Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Insulin Glargine Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Insulin Glargine Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Insulin Glargine Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Insulin Glargine Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Insulin Glargine Injection industry.

Chapter 3: Detailed analysis of Insulin Glargine Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Insulin Glargine Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Insulin Glargine Injection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Insulin Glargine Injection Industry Trends Table 2. Insulin Glargine Injection Industry Drivers Table 3. Insulin Glargine Injection Industry Opportunities and Challenges Table 4. Insulin Glargine Injection Industry Restraints Table 5. Global Insulin Glargine Injection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Insulin Glargine Injection Revenue Share by Company (2021-2026) Table 7. Global Insulin Glargine Injection Sales Volume by Company (k units) & (2021-2026) Table 8. Global Insulin Glargine Injection Sales Volume Share by Company (2021-2026) Table 9. Global Insulin Glargine Injection Average Price (US$/unit) of Company (2021-2026) Table 10. Global Insulin Glargine Injection Company Ranking, (2024-2026) & (USD Million) Table 11. Global Insulin Glargine Injection Key Company Manufacturing Base & Headquarters Table 12. Global Insulin Glargine Injection Company, Product Type & Application Table 13. Global Insulin Glargine Injection Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Insulin Glargine Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Pre-filled Table 18. Significant Companies of Ordinary Table 19. Global Insulin Glargine Injection Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Insulin Glargine Injection Sales Volume by Type (2021-2026) & (k units) Table 21. Global Insulin Glargine Injection Sales Volume by Type (2027-2032) & (k units) Table 22. Global Insulin Glargine Injection Sales Volume Share by Type (2021-2026) Table 23. Global Insulin Glargine Injection Sales Volume Share by Type (2027-2032) Table 24. Global Insulin Glargine Injection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Insulin Glargine Injection Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Insulin Glargine Injection Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Insulin Glargine Injection Sales Value Share by Type (2021-2026) Table 28. Global Insulin Glargine Injection Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Global Insulin Glargine Injection Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Insulin Glargine Injection Sales Volume by Application (2021-2026) & (k units) Table 33. Global Insulin Glargine Injection Sales Volume by Application (2027-2032) & (k units) Table 34. Global Insulin Glargine Injection Sales Volume Share by Application (2021-2026) Table 35. Global Insulin Glargine Injection Sales Volume Share by Application (2027-2032) Table 36. Global Insulin Glargine Injection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Insulin Glargine Injection Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Insulin Glargine Injection Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Insulin Glargine Injection Sales Value Share by Application (2021-2026) Table 40. Global Insulin Glargine Injection Sales Value Share by Application (2027-2032) Table 41. Global Insulin Glargine Injection Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Insulin Glargine Injection Sales by Region (2021-2026) & (k units) Table 43. Global Insulin Glargine Injection Sales Market Share by Region (2021-2026) Table 44. Global Insulin Glargine Injection Sales by Region (2027-2032) & (k units) Table 45. Global Insulin Glargine Injection Sales Market Share by Region (2027-2032) Table 46. Global Insulin Glargine Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Insulin Glargine Injection Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Insulin Glargine Injection Sales Value Share by Region (2021-2026) Table 49. Global Insulin Glargine Injection Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Insulin Glargine Injection Sales Value Share by Region (2027-2032) Table 51. Global Insulin Glargine Injection Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Insulin Glargine Injection Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Insulin Glargine Injection Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Insulin Glargine Injection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Insulin Glargine Injection Sales by Country (2021-2026) & (k units) Table 56. Global Insulin Glargine Injection Sales Market Share by Country (2021-2026) Table 57. Global Insulin Glargine Injection Sales by Country (2027-2032) & (k units) Table 58. Global Insulin Glargine Injection Sales Market Share by Country (2027-2032) Table 59. Global Insulin Glargine Injection Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Insulin Glargine Injection Sales Value Market Share by Country (2021-2026) Table 61. Global Insulin Glargine Injection Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Insulin Glargine Injection Sales Value Market Share by Country (2027-2032) Table 63. Tonghua Dongbao Pharmaceutical Company Information Table 64. Tonghua Dongbao Pharmaceutical Business Overview Table 65. Tonghua Dongbao Pharmaceutical Insulin Glargine Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Tonghua Dongbao Pharmaceutical Insulin Glargine Injection Product Portfolio Table 67. Tonghua Dongbao Pharmaceutical Recent Development Table 68. Sanofi Company Information Table 69. Sanofi Business Overview Table 70. Sanofi Insulin Glargine Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Sanofi Insulin Glargine Injection Product Portfolio Table 72. Sanofi Recent Development Table 73. Boao Bio Harmaceutical Company Information Table 74. Boao Bio Harmaceutical Business Overview Table 75. Boao Bio Harmaceutical Insulin Glargine Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Boao Bio Harmaceutical Insulin Glargine Injection Product Portfolio Table 77. Boao Bio Harmaceutical Recent Development Table 78. Lilly Company Information Table 79. Lilly Business Overview Table 80. Lilly Insulin Glargine Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Lilly Insulin Glargine Injection Product Portfolio Table 82. Lilly Recent Development Table 83. Gan & Lee Company Information Table 84. Gan & Lee Business Overview Table 85. Gan & Lee Insulin Glargine Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Gan & Lee Insulin Glargine Injection Product Portfolio Table 87. Gan & Lee Recent Development Table 88. HEC Pharm Company Information Table 89. HEC Pharm Business Overview Table 90. HEC Pharm Insulin Glargine Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. HEC Pharm Insulin Glargine Injection Product Portfolio Table 92. HEC Pharm Recent Development Table 93. Key Raw Materials Table 94. Raw Materials Key Suppliers Table 95. Insulin Glargine Injection Distributors List Table 96. Insulin Glargine Injection Customers List Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Insulin Glargine Injection Product Image Figure 2. Global Insulin Glargine Injection Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Insulin Glargine Injection Sales Value (2021-2032) & (US$ Million) Figure 4. Global Insulin Glargine Injection Sales (2021-2032) & (k units) Figure 5. Global Insulin Glargine Injection Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Insulin Glargine Injection Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Pre-filled Image Figure 10. Ordinary Image Figure 11. Global Insulin Glargine Injection Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Insulin Glargine Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Insulin Glargine Injection Sales Volume Share by Type (2021-2032) Figure 14. Global Insulin Glargine Injection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Insulin Glargine Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Insulin Glargine Injection Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Global Insulin Glargine Injection Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Insulin Glargine Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Insulin Glargine Injection Sales Volume Share by Application (2021-2032) Figure 22. Global Insulin Glargine Injection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Insulin Glargine Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Insulin Glargine Injection Sales Value Share by Application (2021-2032) Figure 25. Global Insulin Glargine Injection Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Insulin Glargine Injection Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Insulin Glargine Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Insulin Glargine Injection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Insulin Glargine Injection Sales Value (2021-2032) & (US$ Million) Figure 30. North America Insulin Glargine Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Insulin Glargine Injection Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Insulin Glargine Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Insulin Glargine Injection Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Insulin Glargine Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Insulin Glargine Injection Sales Value (2021-2032) & (US$ Million) Figure 36. South America Insulin Glargine Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Insulin Glargine Injection Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Insulin Glargine Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Insulin Glargine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Insulin Glargine Injection Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Insulin Glargine Injection Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Pre-filled
  • Ordinary
Applications
  • Hospital
  • Clinic
Companies covered
  • Tonghua Dongbao Pharmaceutical
  • Sanofi
  • Boao Bio Harmaceutical
  • Lilly
  • Gan & Lee
  • HEC Pharm

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Insulin Glargine Injection Sales Value (2021-2032)
  4. 1.2.2 Global Insulin Glargine Injection Sales Volume (2021-2032)
  5. 1.2.3 Global Insulin Glargine Injection Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Insulin Glargine Injection Market Dynamics
  1. 2.1 Insulin Glargine Injection Industry Trends
  2. 2.2 Insulin Glargine Injection Industry Drivers
  3. 2.3 Insulin Glargine Injection Industry Opportunities and Challenges
  4. 2.4 Insulin Glargine Injection Industry Restraints
3 Insulin Glargine Injection Market by Company
  1. 3.1 Global Insulin Glargine Injection Company Revenue Ranking in 2025
  2. 3.2 Global Insulin Glargine Injection Revenue by Company (2021-2026)
  3. 3.3 Global Insulin Glargine Injection Sales Volume by Company (2021-2026)
  4. 3.4 Global Insulin Glargine Injection Average Price by Company (2021-2026)
  5. 3.5 Global Insulin Glargine Injection Company Ranking (2024-2026)
  6. 3.6 Global Insulin Glargine Injection Company Manufacturing Base and Headquarters
  7. 3.7 Global Insulin Glargine Injection Company Product Type and Application
  8. 3.8 Global Insulin Glargine Injection Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Insulin Glargine Injection Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Insulin Glargine Injection Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Insulin Glargine Injection Market by Type
  1. 4.1 Insulin Glargine Injection Type Introduction
  2. 4.1.1 Pre-filled
  3. 4.1.2 Ordinary
  4. 4.2 Global Insulin Glargine Injection Sales Volume by Type
  5. 4.2.1 Global Insulin Glargine Injection Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Insulin Glargine Injection Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Insulin Glargine Injection Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Insulin Glargine Injection Sales Value by Type
  9. 4.3.1 Global Insulin Glargine Injection Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Insulin Glargine Injection Sales Value by Type (2021-2032)
  11. 4.3.3 Global Insulin Glargine Injection Sales Value Share by Type (2021-2032)
5 Insulin Glargine Injection Market by Application
  1. 5.1 Insulin Glargine Injection Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Insulin Glargine Injection Sales Volume by Application
  5. 5.2.1 Global Insulin Glargine Injection Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Insulin Glargine Injection Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Insulin Glargine Injection Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Insulin Glargine Injection Sales Value by Application
  9. 5.3.1 Global Insulin Glargine Injection Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Insulin Glargine Injection Sales Value by Application (2021-2032)
  11. 5.3.3 Global Insulin Glargine Injection Sales Value Share by Application (2021-2032)
6 Insulin Glargine Injection Regional Sales and Value Analysis
  1. 6.1 Global Insulin Glargine Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Insulin Glargine Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Insulin Glargine Injection Sales by Region: 2021-2026
  4. 6.2.2 Global Insulin Glargine Injection Sales by Region (2027-2032)
  5. 6.3 Global Insulin Glargine Injection Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Insulin Glargine Injection Sales Value by Region (2021-2032)
  7. 6.4.1 Global Insulin Glargine Injection Sales Value by Region: 2021-2026
  8. 6.4.2 Global Insulin Glargine Injection Sales Value by Region (2027-2032)
  9. 6.5 Global Insulin Glargine Injection Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Insulin Glargine Injection Sales Value (2021-2032)
  12. 6.6.2 North America Insulin Glargine Injection Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Insulin Glargine Injection Sales Value (2021-2032)
  15. 6.7.2 Europe Insulin Glargine Injection Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Insulin Glargine Injection Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Insulin Glargine Injection Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Insulin Glargine Injection Sales Value (2021-2032)
  21. 6.9.2 South America Insulin Glargine Injection Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Insulin Glargine Injection Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Insulin Glargine Injection Sales Value Share by Country, 2025 VS 2032
7 Insulin Glargine Injection Country-level Sales and Value Analysis
  1. 7.1 Global Insulin Glargine Injection Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Insulin Glargine Injection Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Insulin Glargine Injection Sales by Country (2021-2032)
  4. 7.3.1 Global Insulin Glargine Injection Sales by Country (2021-2026)
  5. 7.3.2 Global Insulin Glargine Injection Sales by Country (2027-2032)
  6. 7.4 Global Insulin Glargine Injection Sales Value by Country (2021-2032)
  7. 7.4.1 Global Insulin Glargine Injection Sales Value by Country (2021-2026)
  8. 7.4.2 Global Insulin Glargine Injection Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Insulin Glargine Injection Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Insulin Glargine Injection Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Insulin Glargine Injection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Tonghua Dongbao Pharmaceutical
  2. 8.1.1 Tonghua Dongbao Pharmaceutical Company Information
  3. 8.1.2 Tonghua Dongbao Pharmaceutical Business Overview
  4. 8.1.3 Tonghua Dongbao Pharmaceutical Insulin Glargine Injection Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Tonghua Dongbao Pharmaceutical Insulin Glargine Injection Product Portfolio
  6. 8.1.5 Tonghua Dongbao Pharmaceutical Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Insulin Glargine Injection Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Insulin Glargine Injection Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Boao Bio Harmaceutical
  14. 8.3.1 Boao Bio Harmaceutical Company Information
  15. 8.3.2 Boao Bio Harmaceutical Business Overview
  16. 8.3.3 Boao Bio Harmaceutical Insulin Glargine Injection Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Boao Bio Harmaceutical Insulin Glargine Injection Product Portfolio
  18. 8.3.5 Boao Bio Harmaceutical Recent Developments
  19. 8.4 Lilly
  20. 8.4.1 Lilly Company Information
  21. 8.4.2 Lilly Business Overview
  22. 8.4.3 Lilly Insulin Glargine Injection Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Lilly Insulin Glargine Injection Product Portfolio
  24. 8.4.5 Lilly Recent Developments
  25. 8.5 Gan & Lee
  26. 8.5.1 Gan & Lee Company Information
  27. 8.5.2 Gan & Lee Business Overview
  28. 8.5.3 Gan & Lee Insulin Glargine Injection Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Gan & Lee Insulin Glargine Injection Product Portfolio
  30. 8.5.5 Gan & Lee Recent Developments
  31. 8.6 HEC Pharm
  32. 8.6.1 HEC Pharm Company Information
  33. 8.6.2 HEC Pharm Business Overview
  34. 8.6.3 HEC Pharm Insulin Glargine Injection Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 HEC Pharm Insulin Glargine Injection Product Portfolio
  36. 8.6.5 HEC Pharm Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Insulin Glargine Injection Value Chain Analysis
  2. 9.1.1 Insulin Glargine Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Insulin Glargine Injection Sales Mode & Process
  6. 9.2 Insulin Glargine Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Insulin Glargine Injection Distributors
  9. 9.2.3 Insulin Glargine Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst